Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells

Endocrinology

Volumn 145, Issue 7, 2004, Pages 3205-3214

  Wadsworth, Teri L ^a   Carroll, Julie M ^b   Mallinson, Rebecca A ^c   Roberts Jr , Charles T ^b   Roselli, Charles E ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLANT EXTRACT; PROTEIN SHC; S6 KINASE; SAW PALMETTO EXTRACT; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MEDICINAL PLANT; PRIORITY JOURNAL; PROSTATE EPITHELIUM; SABAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROGEN ANTAGONISTS; APOPTOSIS; CELL DIVISION; CELL LINE, TRANSFORMED; CELL SURVIVAL; EPITHELIAL CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLANT EXTRACTS; PROSTATE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SERENOA; SIGNAL TRANSDUCTION;

EID: 3042642995     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-1716     Document Type: Article

References (62)

1. Jacobsen SJ, Girman CJ, Lieber MM 2001 Natural history of benign prostatic hyperplasia. Urology 58:5-16
2. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H 1996 Regulation of prostatic growth and function by peptide growth factors. Prostate 28:392-405
3. Peehl DM, Cohen P, Rosenfeld RG 1995 The insulin-like growth-factor system in the Prostate. World J Urol 13:306-311
4. Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG 1994 Insulin-like growth-factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 79:1410-1415
5. Dong GY, Rajah R, Vu T, Hoffman AR, Rosenfeld RG, Roberts CT, Peehl DM, Cohen P 1997 Decreased expression of Wilms' tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 82:2198-2203
6. LeRoith D, Roberts CT 2003 The insulin-like growth factor system and cancer. Cancer Lett 195:127-137
7. Adams TE, Epa VC, Garrett TPJ, Ward CW 2000 Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57:1050-1093
8. Vivanco I, Sawyers CL 2002 The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2:489-501
9. Ghosh PM, Bedolla R, Mikhailova M, Kreisberg JI 2002 RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Cζ. Cancer Res 62:2630-2636
10. Diehl JA, Cheng MG, Roussel MF, Sherr CJ 1998 Glycogen synthase kinase 3 β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499-3511
11. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N 1998 Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase Akt-dependent pathway. J Biol Chem 273:29864-29872
12. Kandel ES, Hay N 1999 The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253:210-229
13. Grammer TC, Cheatham L, Chou MM, Blenis J 1996 The p70(S6K) signalling pathway: a novel signalling system involved in growth regulation. Cancer Surv 27:271-292
14. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ 2001 p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 98:9666-9670
15. Chen YR, Meyer CF, Tan TH 1996 Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in γ radiation-induced apoptosis. J Biol Chem 271:631-634
16. Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, Wimalasena J 1998 Microtubule-interfering agents activate c-Jun N-terminal kinase stress-activated protein kinase through both ras and apoptosis signal-regulating kinase pathways. J Biol Chem 273:4928-4936
17. Mamay CL, Mingo-Sion AM, Wolf DM, Molina MD, Van Den Berg CL 2003 An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer. Oncogene 22:602-614
18. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF 2002 Phosphorylation of Ser(307) in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277:1531-1537
19. Aguirre V, Uchida T, Yenush L, Davis R, White MF 2000 The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275:9047-9054
20. Herrmann JL, Bruckheimer E, McDonnell TJ 1996 Cell death signal transduction and Bcl-2 function. Biochem Soc Trans 24:1059-1065
21. Steiner JF 1996 Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokin 30:16-27
22. Lowe FC, Fagelman E 2002 Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 12:15-18
23. Gerber GS 2000 Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol 163:1408-1412
24. Wilt TJ, Ishani A, Rutks I, MacDonald R 2000 Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 3:459-472
25. Koch E 2001 Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med 67:489-500
26. Goldmann WH, Sharma AL, Currier SJ, Johnston PD, Rana A, Sharma CP 2001 Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol Int 25:1117-1124
27. Iguchi K, Okumura N, Usui S, Sajiki H, Hirota K, Hirano K 2001 Myristoleic acid, a cytotoxic component in the extract from serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 47:59-65
28. Vacherot F, Azzouz M, Gil-Diez-De-Medina S, Colombel M, de la TA, Lefrere Belda MA, Abbou CC, Raynaud JP, Chopin DK 2000 Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. Prostate 45:259-266
29. Bae VL, Jacksoncook CK, Brothman AR, Maygarden SJ, Ware JL 1994 Tumorigenicity of Sv40 T-antigen immortalized human prostate epithelial-cells - association with decreased epidermal growth-factor receptor (Egfr) expression. Int J Cancer 58:721-729
30. Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J, Ware JL 1998 Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 34:275-282
31. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC 1994 Cleavage of poly(Adp-ribose) polymerase by A proteinase with properties like ice. Nature 371:346-347
32. Marcelli M, Cunningham GR 1999 Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab 84:3463-3468
33. Cohen P, Peehl DM, Lamson G, Rosenfeld RG 1991 Insulin-like growth-factors (Igfs), Igf receptors, and Igf-binding proteins in primary cultures of prostate epithelial-cells. J Clin Endocrinol Metab 73:401-407
34. Hanahan D, Weinberg RA 2000 The hallmarks of cancer. Cell 100:57-70
35. Ravenna L, Di Silverio F, Russo MA, Salvatori L, Morgante E, Morrone S, Cardillo MR, Russo A, Frati L, Gulino A, Petrangeli E 1996 Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate 29:219-230
36. De Bernardi Di Valserra M, Tripode AS 1994 Rectal bioavailability and pharmacokinetics in healthy volunteers of serenoa repens new formulation. Arch Med Intern 46:7-86
37. Chevalier G, Benard P, Cousse H, Bengone T 1997 Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (Permixon(R)) supplemented with [1-C-14]-lauric acid, [1-C-14]-oleic acid or [4-C-14]-β-sitosterol. Eur J Drug Metab Pharmacokin 22:73-83
38. Bayne CW, Ross M, Donnelly F, Habib FK 2000 The selectivity and specificity of the actions of the lipido-sterolic extract of serenoa repens (Permixon (R)) on the prostate. J Urol 164:876-881
39. Garzotto M, Haimovitz-Friedman A, Liao WC, White-Jones M, Huryk R, Heston WDW, Cardon-Cardo C, Kolesnick R, Fuks Z 1999 Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 59:5194-5201
40. Gao N, Zhang Z, Jiang BH, Shi XL 2003 Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310:1124-1132
41. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD 1997 Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22:267-272
42. Kim DS, Kim SY, Kleuser B, Schafer-Korting M, Kim KH, Park KC 2004 Sphingosine-1-phosphate inhibits human keratinocyte proliferation via Akt/protein kinase B inactivation. Cell Signal 16:89-95
43. Salinas M, Lopez-Valdaliso R, Martin D, Alvarez A, Cuadrado A 2000 Inhibition of PKB/Akt1 by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells. Mol Cell Neurosci 15:156-169
44. Klein RD, Fischer SM 2002 Black tea polyphenols inhibit IGF-I-induced signaling through Akt in normal prostate epithelial cells and Du145 prostate carcinoma cells. Carcinogenesis 23:217-221
45. Siddiqui IA, Adhami VM, Afaq F, Ahmad N, Mukhtar H 2004 Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem 91:232-242
46. Kolesnick RN, Kronke M 1998 Regulation of ceramide production and apoptosis. Ann Rev Physiol 60:643-665
47. Bu SZ, Blaukat A, Fu X, Heldin NE, Landstrom M 2002 Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett 531:141-151
48. Haimovitz-Friedman A, Kolesnick RN, Fuks Z 1997 Ceramide signaling in apoptosis. Brit Med Bull 53:539-553
49. Ruvolo PP 2003 Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharm Res 47:383-392
50. Mathias S, Pena LA, Kolesnick RN 1998 Signal transduction of stress via ceramide. Biochem J 335:465-480
51. Shimabukuro M, Zhou YT, Levi M, Unger RH 1998 Fatty acid-induced β cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 95:2498-2502
52. Schmitz-Peiffer C, Craig DL, Biden TJ 1999 Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 274:24202-24210
53. Boon H, Westlake K, Stewart M, Gray R, Fleshner N, Gavin A, Brown JB, Goel V 2003 Use of complementary/alternative medicine by men diagnosed with prostate cancer. Urology 62:849-853
54. Crescioli C, Villari D, Forti G, Ferruzzi P, Petrone L, Vannelli GB, Adorini L, Salerno R, Serio M, Maggi M 2002 Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D-3 analogue. Mol Cell Endocrinol 198:69-75
55. Cohen P 1998 Serum insulin-like growth factor-I levels and prostate cancer risk - interpreting the evidence. J Natl Cancer Inst 90:876-879
56. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M 1998 Plasma insulin-like growth factor I and prostate cancer risk: a prospective study. Science 279:563-566
57. Wu SF, Sun HZ, Qi XD, Tu ZH 2001 Effect of epristeride on the expression of IGF-1 and TGF-β receptors in androgen-induced castrated rat prostate. Exp Biol Med 226:954-960
58. Huynh H, Seyam RM, Brock GB 1998 Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 58:215-218
59. Huynh H, Alpert L, Alaoui-Lamali MA, Ng CY, Chan TWM 2001 Co-administration of finasteride and the pure anti-oestrogen ICI 182,780 act synergistically in modulating the IGF system in rat prostate. J Endocrinol 171:109-118
60. Huynh H 2002 Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol 20:1297-1303
61. Huynh H, Pollak M, Zhang JC 1998 Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer dells by vitamin D metabolite 1,25(OH)(2)D-3 and its analog EB1089. Intl J Oncol 13:137-143
62. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma HF, Kantoff PW, Golub TR, Loda M, Sellers WR 2003 Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci 100:7841-7846